News from the Phase 1 Unit

​We are delighted to congratulate our medical student, Sediga Nateqi, on the successful completion of her master’s thesis “The Potential of Antibody-Drug Conjugates in Biliary Tract Cancer” at the Phase 1 Unit, Rigshospitalet.

​Whole genome sequencing reveals additional insights and opportunities for precision treatment in brain tumor patients.

​Differences in Tumor Mutational Burden Assessment – Results from a National Ring Trial​

​In 2025, the Phase 1 Unit at Rigshospitalet continued to strengthen its position as a leading Nordic site for early-phase clinical research, supporting partners and sponsors in the efficient and safe development of innovative therapies.

ProTarget participated in this year’s ESMO Congress with a poster presentation, sharing results from the first 301 patients enrolled in the trial.

​SETD2 loss does not confer the same mutational signature in CNS tumors as observed in other tumor types – results presented at AACR-NCI-EORT Molecular Targets and Cancer Therapies congress 2025.

Experts and key opinion leaders from science, regulatory authorities, industry and clinic came together in celebration of ten years of early phase hematology trials at the Phase 1 Unit, Rigshospitalet.

​​Please join us on November 15 as we celebrate 10 years of haematology in the Phase 1 Unit at Rigshospitalet. We look forward to seeing you all and expect a day filled with interesting lectures and debates.​​

​In identifying relevant clinical trials and/or targeted therapies for late stage cancer patients genomic profiling is the key. Despite its widespread use genomic profiling sometimes fails. A new letter report on an analysis of failure to carry out genomic profiling. 

​In celebration of the 10-year-anniversary of Copenhagen Prospective Personalized Oncology (CoPPO) experts and key opion leaders joined the symposium at Rigshospitalet Friday 8. March. 160 participants from both Denmark and other countries attended the celebration of groundbreaking advancements in personalized oncology.